Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 27, 1998

View Archived Issues

Biogen: Q4 and FY 1997 highlights

Lilly and Allelix expand research programs

Chesapeake Biological Laboratories and LXR to codevelop Cardiosol products

New approach to cancer therapy reported

Lilly researchers prepare novel 5-HT reuptake inhibitors

Resistance modulators for use in cancer and malaria developed at Lilly

Protein farnesyltransferase inhibitors patented by Pfizer for cancer

Antifungal antibiotics isolated by Takara Shuzo

ADIR prepares MMP inhibitors for arthritis, cancer, atherosclerosis

Takeda discloses compounds that upregulate LDL receptors

ACAT-inhibitory anilides from Kowa are particularly useful for atherosclerosis

U.K. launch for Posicor

Wyeth-Ayerst licenses PEPCK-modulating compounds

New antimigraine combination addresses both headache and vomiting

Progenitor and Affymetrix collaborate on asthma research

New bacterial genomics company established by Theratechnologies

First pivotal trial of lisofylline completed

Mentor obtains marketing rights to new cancer therapeutic from Intracel

New ET antagonists from Merck KGaA bearing a benzothiadiazole functionality

AtheroGenics initiates phase I testing for new cardiovascular drug

Vion prepares more active prodrug of beta-L-FD4C

Phytochemistry alliance formed by Xenova Discovery and IGER

AltaRex reacquires Western European marketing rights to Ovarex

Once-daily hair loss treatment available throughout the U.S.

RTX enters phase II for urge incontinence

New once-daily rosacea therapy introduced in U.S.

Common variant of CETP gene correlated with atherosclerosis progression, response to pravastatin

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 13, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.